Abstract

In order to identify a hemoglobin adduct useful for monitoring of doses of butadiene metabolites, particularly the strongly genotoxic, bifunctional diepoxybutane (DEB), the reaction of DEB with valinamide, a relevant model of globin N-termini, was studied. A preliminary kinetic analysis showed that the primary reaction product of DEB with valine- N gives, as was expected, rise to a ring-closed pyrrolidine-structured compound, N, N-(2,3-dihy-droxybuta-1, 4-diyl)valine (PYRV), in a reaction which is fast when compared to hydrolysis of the second oxirane ring with formation of N-(2,3,4-trihydroxybutyl)valine (THBV). The ring closure is also fast when compared to the rate of formation of a cross-linked divaline product. PYRV can therefore be used as a specific marker of in vivo doses of DEB whereas THBV may be applied for the dosimetry of the metabolite (1,2-dihydroxyethyl)oxirane. The latter is formed by half-hydrolysis of DEB or oxygenation of 1,2-dihydroxy-3-butene. The N-alkyl Edman method, used for specific cleavage and gas chromatographic/mass spectrometric (GC/MS) determination of adducts to N-terminal valine in hemoglobin, could be used for measurement of THBV, as shown in alkylation experiments with blood. However, the adduct specific for DEB, PYRV, requires—due to its tertiary amine structure—other techniques. The reaction products were identified by GC/MS, PYRV by 13C and 1H NMR, and THBV because of its formation by reduction of the Schiff bases of threose and erythrose with hemoglobin.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call